Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
 |
Int J Clin Pract Suppl. 1999 Jun;103:30-4. Unique Identifier : AIDSLINE MED/20087921
Moyle G; Chelsea and Westminster Hospital, London, UK.
Abstract: Concerns about the long-term safety issues with protease inhibitors (PIs) and recent reports of non-PI-containing regimens demonstrating potent and durable suppression of viral replication have brought into question the role of PI therapy. However, a number of issues surrounding PI-sparing regimens, such as the durability of the antiretroviral effect, the virologic benefits in sanctuary sites, and the extent of changes in immune function, need to be clarified. The role of efavirenz in both PI-sparing first-line and salvage regimens is currently being investigated. Evidence to date has indicated that efavirenz has a highly potent and durable antiviral activity in such regimens. Efavirenz is well tolerated with adverse events generally being mild in intensity and infrequently prompting discontinuation.
000430
A0040885
Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .